New Study Addresses ‘$28 Billion Problem’ of Research Fidelity
In the U.S. alone, around $28 billion a year is spent on preclinical research that is not reproducible, and low reproducibility rates contribute to both delays and costs of therapeutic drug development.
In the U.S. alone, around $28 billion a year is spent on preclinical research that is not reproducible, and low reproducibility rates contribute to both delays and costs of therapeutic drug development, according to a study published on June 9th, 2015 in the PLOS Biology journal by the Global Biological Standards Institute (GBSI) and two economists.
Analysis of past life science research studies indicates that the cumulative prevalence of irreproducible preclinical research exceeds 50%, and action is now required, noted the three authors, Drs. Leonard P. Freedman, Iain M. Cockburn and Timothy S. Simcoe.
"To achieve greatest levels of reproducibility, The Economics of Reproducibility in Preclinical Research offers tangible solutions - providing guidelines for advancing education and training and applying best practices in life science research. The valuable time, money and resources saved will mean finding faster treatments and cures," stated Freedman, who is president of GBSI.
Reviewing publicly available data from government sources, industry and analyst reports and scientific articles, the authors conducted an in-depth analysis of the key components of irreproducibility and used secondary research to benchmark the potential impact of improved standards. They think the causes of irreproducible research can be grouped into four categories: biological reagents and reference materials, study design, data analysis and reporting, and laboratory protocols. Of these, errors in biological reagents and materials (36% of total) and study design (28% of total) are the two largest factors.
By categorizing the root causes of irreproducibility and estimating their relative importance, it is possible to prioritize potential solutions, and ultimately, increase the overall return on public and private investments in research and development, they explained.
"Improving reproducibility levels will require a measured investment in time and resources," noted Cockburn. "We recommend investing in practical solutions and taking immediate steps in the areas where there will be the greatest return on investment."
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
